Cargando…

Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial

Chronic low back pain (CLBP) is a disabling condition worldwide. In CLBP, neuroimaging studies demonstrate abnormal activities in cortical areas responsible for pain modulation, emotional, and sensory components of pain experience [i.e., pregenual and dorsal anterior cingulate cortex (pgACC, dACC),...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhia, Divya Bharatkumar, Mani, Ramakrishnan, Mathew, Jerin, O’Leary, Finella, Smith, Mark, Vanneste, Sven, De Ridder, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860016/
https://www.ncbi.nlm.nih.gov/pubmed/36670176
http://dx.doi.org/10.1038/s41598-023-28344-2
_version_ 1784874479306932224
author Adhia, Divya Bharatkumar
Mani, Ramakrishnan
Mathew, Jerin
O’Leary, Finella
Smith, Mark
Vanneste, Sven
De Ridder, Dirk
author_facet Adhia, Divya Bharatkumar
Mani, Ramakrishnan
Mathew, Jerin
O’Leary, Finella
Smith, Mark
Vanneste, Sven
De Ridder, Dirk
author_sort Adhia, Divya Bharatkumar
collection PubMed
description Chronic low back pain (CLBP) is a disabling condition worldwide. In CLBP, neuroimaging studies demonstrate abnormal activities in cortical areas responsible for pain modulation, emotional, and sensory components of pain experience [i.e., pregenual and dorsal anterior cingulate cortex (pgACC, dACC), and somatosensory cortex (SSC), respectively]. This pilot study, conducted in a university setting, evaluated the feasibility, safety, and acceptability of a novel electroencephalography-based infraslow-neurofeedback (EEG ISF-NF) technique for retraining activities in pgACC, dACC and SSC and explored its effects on pain and disability. Participants with CLBP (n = 60), recruited between July’20 to March’21, received 12 sessions of either: ISF-NF targeting pgACC, dACC + SSC, a ratio of pgACC*2/dACC + SSC, or Placebo-NF. Descriptive statistics demonstrated that ISF-NF training is feasible [recruitment rate (7 participants/month), dropouts (25%; 20–27%), and adherence (80%; 73–88%)], safe (no adverse events reported), and was moderate to highly acceptable [Mean ± SD: 7.8 ± 2.0 (pgACC), 7.5 ± 2.7 (dACC + SCC), 8.2 ± 1.9 (Ratio), and 7.7 ± 1.5 (Placebo)]. ISF-NF targeting pgACC demonstrated the most favourable clinical outcomes, with a higher proportion of participants exhibiting a clinically meaningful reduction in pain severity [53%; MD (95% CI): − 1.9 (− 2.7, − 1.0)], interference [80%; MD (95% CI): − 2.3 (− 3.5, − 1.2)], and disability [73%; MD (95% CI): − 4.5 (− 6.1, − 2.9)] at 1-month follow-up. ISF-NF training is a feasible, safe, and an acceptable treatment approach for CLBP.
format Online
Article
Text
id pubmed-9860016
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98600162023-01-22 Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial Adhia, Divya Bharatkumar Mani, Ramakrishnan Mathew, Jerin O’Leary, Finella Smith, Mark Vanneste, Sven De Ridder, Dirk Sci Rep Article Chronic low back pain (CLBP) is a disabling condition worldwide. In CLBP, neuroimaging studies demonstrate abnormal activities in cortical areas responsible for pain modulation, emotional, and sensory components of pain experience [i.e., pregenual and dorsal anterior cingulate cortex (pgACC, dACC), and somatosensory cortex (SSC), respectively]. This pilot study, conducted in a university setting, evaluated the feasibility, safety, and acceptability of a novel electroencephalography-based infraslow-neurofeedback (EEG ISF-NF) technique for retraining activities in pgACC, dACC and SSC and explored its effects on pain and disability. Participants with CLBP (n = 60), recruited between July’20 to March’21, received 12 sessions of either: ISF-NF targeting pgACC, dACC + SSC, a ratio of pgACC*2/dACC + SSC, or Placebo-NF. Descriptive statistics demonstrated that ISF-NF training is feasible [recruitment rate (7 participants/month), dropouts (25%; 20–27%), and adherence (80%; 73–88%)], safe (no adverse events reported), and was moderate to highly acceptable [Mean ± SD: 7.8 ± 2.0 (pgACC), 7.5 ± 2.7 (dACC + SCC), 8.2 ± 1.9 (Ratio), and 7.7 ± 1.5 (Placebo)]. ISF-NF targeting pgACC demonstrated the most favourable clinical outcomes, with a higher proportion of participants exhibiting a clinically meaningful reduction in pain severity [53%; MD (95% CI): − 1.9 (− 2.7, − 1.0)], interference [80%; MD (95% CI): − 2.3 (− 3.5, − 1.2)], and disability [73%; MD (95% CI): − 4.5 (− 6.1, − 2.9)] at 1-month follow-up. ISF-NF training is a feasible, safe, and an acceptable treatment approach for CLBP. Nature Publishing Group UK 2023-01-20 /pmc/articles/PMC9860016/ /pubmed/36670176 http://dx.doi.org/10.1038/s41598-023-28344-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Adhia, Divya Bharatkumar
Mani, Ramakrishnan
Mathew, Jerin
O’Leary, Finella
Smith, Mark
Vanneste, Sven
De Ridder, Dirk
Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial
title Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial
title_full Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial
title_fullStr Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial
title_full_unstemmed Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial
title_short Exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial
title_sort exploring electroencephalographic infraslow neurofeedback treatment for chronic low back pain: a double-blinded safety and feasibility randomized placebo-controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860016/
https://www.ncbi.nlm.nih.gov/pubmed/36670176
http://dx.doi.org/10.1038/s41598-023-28344-2
work_keys_str_mv AT adhiadivyabharatkumar exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial
AT maniramakrishnan exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial
AT mathewjerin exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial
AT olearyfinella exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial
AT smithmark exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial
AT vannestesven exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial
AT deridderdirk exploringelectroencephalographicinfraslowneurofeedbacktreatmentforchroniclowbackpainadoubleblindedsafetyandfeasibilityrandomizedplacebocontrolledtrial